

STUDY OF RELATION BETWEEN HCV AND DYSLIPIDAEMIA IN HEMODIALYSIS PATIENTS AND IMPACT ON ATHEROSCLEROSIS

Thesis

*Submitted for Partial Fulfillment of Master Degree
of Internal Medicine*

By

Walid Abdalla Attia Salem
M.B. B.Ch

Supervised By

Prof. Dr. / Hisham Mohammed Elsayed
*Prof. of Internal Medicine & Nephrology
Faculty of Medicine Ain Shams University*

Ass. Prof. Dr. / Sahar Mahmoud Shawky
*Ass. Prof. of Internal Medicine & Nephrology
Faculty of Medicine Ain Shams University*

**Faculty of Medicine
Ain Shams University**

٢٠١٢

Acknowledgement

First of all praise and thanks to **ALLAH** providing me with time and effort to accomplish this thesis.

I wish to express my deep gratitude to Prof. Dr. Hisham Mohammed Elsayed, Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University for his enthusiasm, meticulous guidance, precious remarks and follow up throughout this work. I had the honor to work under his supervision, and his scientific remarks are beyond acknowledgement.

I am greatly indebted to Dr. Sahar Mahmoud Shawky, Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, for her continuous encouragement and sincere contribution in this work with her time and effort.

Lastly but not least I would like to extend my warm thanks to my all professors and colleagues in Kobbry Alkobbba Medical Military Compound for their continuous help and support.

At the end I would like to express my sincere gratitude and great indebtedness to those who gave me everything and not waiting for any reward, to my great parents, sisters and brothers and my wife to whom I owe more than any words can express.

Contents

	<u>Page</u>
List of Abbreviations	I
List of Tables	V
List of Figures	VIII
Protocol	XI
 Introduction and Aim of the Work	 ۱
<u>Review of Literature</u>	
I- Atherosclerosis	۵
▪ Definition	۷
▪ Pathophysiology of atherosclerosis	۹
▪ Clinical features	۱۲
▪ Diagnosis and monitoring of atherosclerosis	۱۴
▪ Prevention and treatment of atherosclerosis	۱۶
 II- Chronic kidney disease	 ۱۹
▪ Definition	۱۹
▪ Classification	۲۰
▪ Pathophysiology	۲۲
▪ Clinical picture	۲۲
▪ Comorbidities and complications	۲۳
▪ Diagnosis and screening	۲۵
▪ Treatment	۲۷
▪ Hemodialysis complications	۳۲

III- Hepatitis C virus	٤٠
▪ Structure	٤١
▪ Risk factors and transmission	٤٣
▪ Diagnosis and screening of hepatitis C	٤٤
▪ Long term complications	٤٧
▪ Management	٥٣
▪ Hepatitis C among hemodialysis patients	٥٨
▪ Impact of HCV on atherosclerosis in HD patients	٧٠
IV- Dyslipidaemia	٧٧
▪ Lipids and Lipoproteins	٧٧
▪ Definition of Dyslipidemia	٨٢
▪ Classification of Dyslipidemia	٨٣
▪ Diagnosis and Screening	٨٧
▪ Treatment	٩٠
▪ Dyslipidemia and kidney disease	٩٣
▪ Impact of Dyslipidemia on Atherosclerosis in HD patients	١٠٩
Subjects and methods	١١٣
Results	١١٧
Discussion	١٤٥
Summary	١٥٤
Conclusion	١٥٨
Recommendations	١٥٩
References	١٦٠
Arabic Summary	_____

List of Abbreviations

Ab	Antibody
ACE	Angiotensin converting enzymes
ADPKD	Autosomal dominant polycystic kidney disease
AIDS	Acquired immunodeficiency syndrome
AKI	Acute kidney injury
ALT	Alanine aminotransferase
Ang II	Angiotensin II
apo	Apolipoprotein
ARBs	Angiotensin receptor blockers
ARIC	Atherosclerosis risk in communities
ASCVD	Atherosclerotic cardiovascular disease
AST	Aspartate aminotransferase
ATP III	The adult treatment panel III
AV	Arteriovenous
bdNA	Branched DNA
BMI	Body mass index
CAD	Coronary artery disease
C_{Cr}	Creatinine clearance
CDC	Centres for disease control
CHC	Chronic hepatitis C
CHD	Coronary heart disease
CIMT	Carotid intima-media thickness
CKD	Chronic kidney disease
CRF	Chronic renal failure
CRI	Chronic renal impairment

CT	Computed tomography
CV	Cardiovascular
CVCs	Central venous catheters
CVD	Cardiovascular disease
DVT	Deep venous thrombosis
EC dysfunction	Endothelial dysfunction
eGFR	Estimated glomerular filtration rate
EIA	Enzyme immunoassay
ELISA	Enzyme linked immunosorbent assay
ESRD	End stage renal disease
ETR	End of treatment response
EVR	Early virological response
FSGS	Focal and segmental glomerulosclerosis
GFR	Glomerular filtration rate
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HCVcAg	HCV core antigen
HD	Hemodialysis
HDL	High density lipoproteins
HGF	Hepatocyte growth factor
HIV	Human immunodeficiency virus
HMGR	Hydroxy- γ methyl glutaryl-coenzyme A reductase
IDL	Intermediate density lipoproteins
IFN	Interferon
IL-γ	Interleukin γ

IMT	Intima media thickness
IVUS	Intravascular ultrasound
K/DOQI	Kidney disease outcomes quality initiative
KDIGO	Kidney disease improving global outcomes
LCAT	Lecithin-cholesterol acyltransferase
LDL	Low density lipoproteins
LMWH	Low molecular weight heparin
Lp (a)	Lipoprotein (a)
LPL	Lipoprotein lipase
MC	Mixed cryoglobulinemia
MDRD	Modification of diet in renal disease
MHC	Major histocompatibility
MHD	Maintenance hemodialysis
MICS	Malnutrition inflammation complex syndrome
MN	Membranous nephropathy
MPGN	Membranoproliferative glomerulonephritis
MRI	Magnetic resonance imaging
NCEP III	National cholesterol education program
NHANES III	National health and nutrition examination survey
NHL	Non-Hodgkin's lymphoma
NKF	National kidney foundation
oxLDL	Oxidized low density lipoproteins
PAF	Platelet activating factor
PBMC	Peripheral blood mononuclear cells
PCR	Polymerase chain reaction
PCT	Porphyria cutanea tarda

PEGIFN	Pegylated interferon
P_{GC}	Glomerular capillary hydraulic pressure
PPAR_α	Peroxisome proliferated activated nuclear receptor
PUFA	Polyunsaturated fatty acids
PVD	Peripheral vascular disease
RA	Rheumatoid arthritis
RIBA	Recombinant immunoblot assay
RT	Reverse transcriptase
RT-PCR	Reverse transcriptase polymerase chain reaction
S_{Cr}	Serum creatinine concentration
SNGFR	Single nephron glomerular filtration rate
SS	Sjogren's syndrome
SVR	Sustained virological response
TGs	Triglycerides
TIAs	Transient ischemic attacks
TIF	Tubulointerstitial fibrosis
TMA	Transcription mediated amplification
TNF	Tumor necrosis factor
TRL	Triglyceride rich lipoproteins
USPSTF	The united states preventive services task force
UTRs	Untranslated regions
VLDL	Very low density lipoproteins

List of Tables

<i>Table No.</i>	<i>Page</i>
Table (١): Major risk factors of atherosclerosis other than LDL-C	١٦
Table (٢): Secondary prevention goals for coronary and atherosclerotic disease	١٨
Table (٣): Risk factors for developing chronic HCV infection	٤٥
Table (٤): Risk factors for advanced progression of liver fibrosis	٤٥
Table (٥): HCV Ab prevalence in Egypt	٦١
Table (٦): Classification of Lipoproteins	٧٩
Table (٧): The NCEP classification of dyslipidemia	٨٣
Table (٨): The Fredrickson classification	٨٣
Table (٩): Causes of secondary dyslipidemia	٨٦
Table (١٠): Risk factors for dyslipidemia	٨٦

Table (١١):	٨٧
Signs and symptoms of dyslipidemia	
Table (١٢):	٩٠
The therapeutic strategy for patients with dyslipidemia	
Table (١٣):	٩٢
Drugs affecting lipoprotein metabolism	
Table (١٤):	١٠٨
Proposed treatment algorithm for lipid management in patients with CKD (Stage ٣ to ٥)	
Table (١٥):	١١٧
Sex distribution between all groups	
Table (١٦):	١١٨
Comparison between group ١ and group ٢ as regard some demographic and biochemical data	
Table (١٧):	١١٩
Comparison between group ١ and group ٢ as regard lipid profile	
Table (١٨):	١٢٠
Comparison between group ١ and group ٢ regarding CRP	
Table (١٩):	١٢١
Comparison between group ١ and group ٢ regarding atherosclerosis	
Table (٢٠):	١٢٢
Comparison between atherosclerosis negative and positive regarding some demographic and biochemical data using Independent-samples T test	

Table (٢١):	١٢٤
Comparison between atherosclerosis negative and positive as regard to lipid profile using Independent-samples T test	
Table (٢٢):	١٢٦
Correlation between total cholesterol (mg/dl) and all studied parameters in all groups	
Table (٢٣):	١٣٠
Correlation between LDL (mg/dl) and all studied parameters in all groups	
Table (٢٤):	١٣٤
Correlation between HDL (mg/dl) and all studied parameters in all groups	
Table (٢٥):	١٣٨
Correlation between non-HDL (mg/dl) and all studied parameters in all groups	
Table (٢٦):	١٤٢
Correlation between triglycerides (mg/dl) and all studied parameters in all groups	

List of Figures

<i>Figure No.</i>	<i>Page</i>
Figure (١)٦	
Sequence of progression of atherosclerosis	
Figure (٢) ١١	
Development of atherosclerotic lesions according to “response to injury” hypothesis	
Figure (٣) ١١	
Risk factors of atherosclerosis	
Figure (٤) ٤١	
Structure of hepatitis C virus	
Figure (٥) ٤٢	
A simplified diagram of the HCV replication cycle	
Figure (٦) ٤٨	
Natural history of HCV infection	
Figure (٧) ٤٩	
Leukocytoclastic vasculitis	
Figure (٨) ٥١	
Lichen planus	
Figure (٩) ٥١	
Porphyria cutanea tarda	

Figure (١٠)	٥٥
The use of HCV virological tools in the treatment of chronic hepatitis C genotype ١	
Figure (١١)	٥٦
The use of HCV virological tools in the treatment of chronic hepatitis C genotypes ٢, ٣	
Figure (١٢)	٥٧
The use of HCV virological tools in the treatment of chronic hepatitis C genotypes ٤, ٥ and ٦	
Figure (١٣)	٦٩
Chronic kidney disease and hepatitis C infection	
Figure (١٤)	٧٧
Structure of lipoproteins	
Figure (١٥)	٧٨
Classification of lipoproteins	
Figure (١٦)	٨١
Major normal lipoprotein metabolic pathways	
Figure (١٧)	٨٩
Algorithm to screen for high cholesterol in adolescents	
Figure (١٨)	١٠٦
Schematic representation of the causes and consequences of malnutrition inflammation complex syndrome	
Figure (١٩)	١١٢
Scheme showing the interaction of risk factors for CKD progression with pathophysiological mechanisms those contribute to a vicious cycle of progressive nephron loss	

Figure (٢٠)	١١٧
Sex distribution between all groups	
Figure (٢١)	١١٩
Comparison between group ١ and group ٢ as regard lipid profile	
Figure (٢٢)	١٢٠
Comparison between group ١ and group ٢ regarding CRP	
Figure (٢٣)	١٢١
Comparison between all groups regarding atherosclerosis	
Figure (٢٤)	١٢٤
Comparison between atherosclerosis negative and positive as regard to lipid profile using Independent-samples T test	

**STUDY OF RELATION BETWEEN HCV AND
DYSLIPIDAEMIA IN HEMODIALYSIS PATIENTS
AND IMPACT ON ATHEROSCLEROSIS**

**Protocol of Thesis
Submitted for Partial Fulfillment of Master
Degree of Internal Medicine**

**By
Walid Abdalla Attia Salem
M.B. B.Ch**

**Supervised By
Prof. Dr. / Hisham Mohammed Elsayed
Prof. of Internal Medicine & Nephrology
Faculty of Medicine Ain Shams University**

**Dr. / Sahar Mahmoud Shawky
Lecturer of Internal Medicine & Nephrology
Faculty of Medicine Ain Shams University**

**Faculty of Medicine
Ain Shams University**

٢٠١٠